mt logoMyToken
ETH Gas
简体中文

Moderna Hits Fresh 52-Week High as Bernstein Calls Intismeran Clearest mRNA Platform Validation, Keeps $45 Target

Moderna Hits Fresh 52-Week High as Bernstein Calls Intismeran Clearest mRNA Platform Validation, Keeps $45 Target

Moderna Inc. (NASDAQ: MRNA) shares set a fresh 52-week high Friday before giving back the intraday advance, while Bernstein SocGen Group reiterated its Market Perform rating and $45 price target and called intismeran the clearest validation yet of Moderna’s broader mRNA therapeutics platform.

Visit Website

免责声明:本文版权归原作者所有,不代表MyToken(www.mytokencap.com)观点和立场;如有关于内容、版权等问题,请与我们联系。
更多精彩内容请查阅
X(https://x.com/MyTokencap)
或加入社区了解更多MyToken-官方华文电报群
(https://t.me/mytoken_cn)
相关阅读